A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR

The recurrent IGH translocations in myeloma define biologically important subgroups of disease that are not only associated with prognosis, but are also characterised by the unique overexpression of potentially targetable proteins.1, 2, 3, 4 Inhibitors of MMSET or FGFR3, both overexpressed in t(4;14) myeloma, or MEK kinase inhibitors, targeting downstream effectors of MAF in cases with t(14;16), are currently under development.5, 6, 7 Thus, identifying these translocation groups in the clinic will become essential for a personalised treatment approach. Expression of a translocation target gene together with the expression of a D group cyclin has been used as a disease classifier for myeloma (TC classification). Here, we have developed a novel test for the detection of the TC groups using multiplexed real-time quantitative reverse transcriptase-PCR (qRT-PCR).